iBio (IBIO) Total Non-Current Liabilities (2022 - 2023)
iBio (IBIO) posted quarterly Total Non-Current Liabilities of $24.2 million for Q3 2023, down 4.32% quarter-over-quarter from $25.3 million in Q2 2023.
iBio (IBIO) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
iBio (IBIO) has reported Total Non-Current Liabilities for 2 consecutive years, with $24.2 million the latest figure, recorded in Q3 2023.
- In Q3 2023, Total Non-Current Liabilities changed N/A year-over-year to $24.2 million; the TTM figure through Sep 2023 stood at $24.2 million (changed N/A YoY), while the FY2023 annual figure was $25.3 million, changed N/A from the prior year.
- Total Non-Current Liabilities declined to $24.2 million in Q3 2023 per IBIO's latest filing, from $25.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $31.9 million in Q4 2022 and bottomed at $24.2 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.32 Bn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 24.21 Mn |
| Jun 30, 2023 | 25.30 Mn |
| Mar 31, 2023 | 26.21 Mn |
| Dec 31, 2022 | 31.91 Mn |